HomeCompareXCAPX vs JNJ

XCAPX vs JNJ: Dividend Comparison 2026

XCAPX yields 7.19% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 XCAPX wins by $12.2K in total portfolio value
10 years
XCAPX
XCAPX
● Live price
7.19%
Share price
$27.81
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.2K
Annual income
$1,135.15
Full XCAPX calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — XCAPX vs JNJ

📍 XCAPX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodXCAPXJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, XCAPX + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
XCAPX pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

XCAPX
Annual income on $10K today (after 15% tax)
$611.29/yr
After 10yr DRIP, annual income (after tax)
$964.88/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, XCAPX beats the other by $261.26/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of XCAPX + JNJ for your $10,000?

XCAPX: 50%JNJ: 50%
100% JNJ50/50100% XCAPX
Portfolio after 10yr
$26.1K
Annual income
$981.47/yr
Blended yield
3.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

XCAPX
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

XCAPX buys
5
JNJ buys
0
PoliticianChamberTickerTypeAmountDate
Thomas R. Carper🏛 Senate$XCAPX▲ Buy$15,001 - $50,0002021-01-29
Thomas R. Carper🏛 Senate$XCAPX▲ Buy$15,001 - $50,0002021-01-29
Thomas R. Carper🏛 Senate$XCAPX▲ Buy$1,001 - $15,0002020-11-30
Thomas R. Carper🏛 Senate$XCAPX▲ Buy$15,001 - $50,0002020-05-28
Thomas R. Carper🏛 Senate$XCAPX▲ Buy$15,001 - $50,0002020-05-28
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricXCAPXJNJ
Forward yield7.19%3.36%
Annual dividend / share$2.00$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$32.2K$20.0K
Annual income after 10y$1,135.15$827.78
Total dividends collected$9.3K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: XCAPX vs JNJ ($10,000, DRIP)

YearXCAPX PortfolioXCAPX Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,419$719.17$10,676$355.77+$743.00XCAPX
2$12,986$767.50$11,407$389.39+$1.6KXCAPX
3$14,711$815.71$12,198$426.53+$2.5KXCAPX
4$16,604$863.60$13,056$467.62+$3.5KXCAPX
5$18,677$910.98$13,987$513.12+$4.7KXCAPX
6$20,942$957.69$14,998$563.56+$5.9KXCAPX
7$23,412$1,003.59$16,098$619.52+$7.3KXCAPX
8$26,099$1,048.53$17,295$681.69+$8.8KXCAPX
9$29,019$1,092.42$18,599$750.82+$10.4KXCAPX
10$32,185$1,135.15$20,022$827.78+$12.2KXCAPX

XCAPX vs JNJ: Complete Analysis 2026

XCAPXStock

ACAP Strategic Fund acts as closed-end investment fund/investment trust. Its objective is to achieve maximum capital appreciation. The company was founded in June, 2009 and is headquartered in New York, NY.

Full XCAPX Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this XCAPX vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

XCAPX vs SCHDXCAPX vs JEPIXCAPX vs OXCAPX vs KOXCAPX vs MAINXCAPX vs ABBVXCAPX vs MRKXCAPX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.